Sydney, April 16, 2007 (ABN Newswire) - Bioprospect Limited (ASX: BPO) - Farm-in Agreement with Solagran - Mr Warwick Dowse, MD; Boardroomradio is pleased to announce that Bioprospect Limited (ASX: BPO) has published an audio file. The following presentation "Farm-in Agreement with Solagran" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: Bioprospect Limited (ASX: BPO)
Broadcast Title: Farm-in Agreement with Solagran
Broadcast Type: Audio stream
View the Audio stream for Bioprospect Limited (ASX: BPO) below.
http://www.brr.com.au/event/BPO/1253/22007/wmp/221.242.254.150/?
PodCast Link:
About Boardroom Media
Boardroom.Media is a new breed of media company that's equal parts publisher, content producer, and streaming media technology business. With a strong footing in capital markets, professional services and asset management, the company has been a leading provider of multimedia communication solutions for corporate Australia for more than a decade.
About Medibio Ltd
Medibio Ltd (ASX:MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Melbourne, VIC, Medibio is listed on the Australian Securities Exchange.
